Your browser doesn't support javascript.
loading
The NOGO receptor NgR2, a novel αVß3 integrin effector, induces neuroendocrine differentiation in prostate cancer.
Quaglia, Fabio; Krishn, Shiv Ram; Sossey-Alaoui, Khalid; Rana, Priyanka Shailendra; Pluskota, Elzbieta; Park, Pyung Hun; Shields, Christopher D; Lin, Stephen; McCue, Peter; Kossenkov, Andrew V; Wang, Yanqing; Goodrich, David W; Ku, Sheng-Yu; Beltran, Himisha; Kelly, William K; Corey, Eva; Klose, Maja; Bandtlow, Christine; Liu, Qin; Altieri, Dario C; Plow, Edward F; Languino, Lucia R.
Afiliação
  • Quaglia F; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.
  • Krishn SR; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Sossey-Alaoui K; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.
  • Rana PS; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Pluskota E; Department of Medicine, School of Medicine, MetroHealth Medical Center, Rammelkamp Center for Research, Case Western Reserve University, Cleveland, OH, USA.
  • Park PH; Department of Medicine, School of Medicine, MetroHealth Medical Center, Rammelkamp Center for Research, Case Western Reserve University, Cleveland, OH, USA.
  • Shields CD; Cardiovascular and Metabolic Sciences Department, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Lin S; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.
  • McCue P; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Kossenkov AV; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.
  • Wang Y; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Goodrich DW; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.
  • Ku SY; Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Beltran H; Department of Pathology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Kelly WK; Center for Systems and Computational Biology, Wistar Institute, Philadelphia, PA, USA.
  • Corey E; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Klose M; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Bandtlow C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Liu Q; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Altieri DC; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Plow EF; Department of Urology, University of Washington, Seattle, WA, USA.
  • Languino LR; Institute of Neurochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Sci Rep ; 12(1): 18879, 2022 11 07.
Article em En | MEDLINE | ID: mdl-36344556
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Carcinoma Neuroendócrino / Receptor Nogo 2 Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Carcinoma Neuroendócrino / Receptor Nogo 2 Idioma: En Ano de publicação: 2022 Tipo de documento: Article